Skip to main content
Loading

AKSO Biopharmaceutical

October 15, 2024
Hunt Room
Multiple Therapeutics
AKSO Biopharmaceutical
Drug-target binding affinity is pivotal in determining therapeutic efficacy. AKSO Bio's proprietary DEEP protein engineering platform, enhanced with AI, not only invents biologic therapeutics with ultra-strong binding affinities in the femtomolar range but also facilitates the discovery of designer molecules for complex targets such as GPCRs through our unique liposomal-based expression system. AKSO Bio is vigorously advancing numerous in-house programs across a broad spectrum of therapeutic areas, with significant investments in autoimmune diseases, fibrosis, and oncology. Our bispecific oncology asset, AB002, has received IND clearance and is poised for clinical advancement.
Speakers
Rebecca Miao - PhD, Chief Scientific Officer - AKSO Biopharmaceutical, Inc.

DOUBLE HELIX SPONSOR

HELIX SPONSOR

PREMIER SPONSOR

CONFERENCE SPONSORS